ARMADA

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company leverages a proprietary synthetic biology platform to engineer high-purity phage cocktails designed to target specific pathogens while sparing the patient's microbiome. Armata's lead programs include AP-SA02 for the treatment of Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa infections in patients with cystic fibrosis. With in-house cGMP manufacturing capabilities, the company is positioned to advance its candidates from discovery through late-stage clinical trials. Armata aims to address the global health crisis of antimicrobial resistance by providing a precise, non-antibiotic alternative for life-threatening systemic and chronic infections.